التفاصيل البيبلوغرافية
| العنوان: |
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial |
| المؤلفون: |
Nolwenn Hall, Clotilde Allavena, Christine Katlama, Alexandra Jobert, Jean-Michel Molina, Eric Cua, Firouzé Bani-Sadr, Laurent Hocqueloux, Claudine Duvivier, Dominique Merrien, Hitoto Hikombo, Elisabeth André-Garnier, Aurélie Gaultier, François Raffi, the QDISS Study Group |
| المصدر: |
AIDS Research and Therapy, Vol 19, Iss 1, Pp 1-6 (2022) |
| بيانات النشر: |
BMC, 2022. |
| سنة النشر: |
2022 |
| المجموعة: |
LCC:Immunologic diseases. Allergy |
| مصطلحات موضوعية: |
HIV-1 infection, Raltegravir, Once daily, Integrase inhibitor, Maintenance, Switch, Immunologic diseases. Allergy, RC581-607 |
| الوصف: |
Abstract Background Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200 mg once daily (qd) for first-line therapy is well established. We assessed efficacy and safety of RAL 1200 mg qd, as part of triple combined antiretroviral therapy (cART), for maintenance strategy. Methods The QDISS trial (NCT03195452) was a 48-week multicenter, single-arm, open-label study designed to evaluate the ability of 2 NRTIs + RAL 1200 mg qd to maintain virological suppression in HIV-1 infected subjects on a stable cART with 2 NRTIs and a third agent for at least 6 months. The primary endpoint was the proportion of participants with HIV-1 RNA |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1742-6405 |
| Relation: |
https://doaj.org/toc/1742-6405 |
| DOI: |
10.1186/s12981-022-00428-5 |
| URL الوصول: |
https://doaj.org/article/92db89510b02477094df275432b25b0c |
| رقم الانضمام: |
edsdoj.92db89510b02477094df275432b25b0c |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder